The large EPS and revenue beat is driven by non-recurring milestones and royalty payments, not core operating leverage. Watch for XmAb819 FDA engagement in 1H27 and the XENITH-UC interim analysis around year-end 2026 for pipeline catalysts.
Drugs in focus
XNCR drug pipeline →XmAb819
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1
- Time to market
- Unknown — pivotal study start is planned for 2027, meaning FDA approval would likely be several years away if Phase 2/3 data are positive.
- Next catalyst
- None dated
What to watchWatch the ESMO 2026 oral presentation (likely October 2026) for updated Phase 1 dose-expansion data, specifically whether the 25% ORR holds or improves in a larger cohort and whether the safety profile (primarily Grade 1-2 CRS, rash, GI events) remains manageable. The pivotal study start in 2027 is the next major milestone after that. XNCR's ~$26 stock price already reflects a mean analyst target of $29, limiting near-term upside absent a clear data beat.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $34.05entry
- T+1 · 11d ago +4.99%α +4.68% · $35.75
- T+5 · 5d ago +11.98%α +8.69% · $38.13
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xencor reported Q3 2026 revenue of $116.5M (vs consensus $63.0M) and GAAP diluted EPS of $0.50 (vs consensus $-0.34), driven by milestone and royalty revenue from partners. The beat was largely non-operational, reflecting a $25M Astellas milestone and $52.5M Alexion settlement payment, while R&D spending rose to $84.3M. Pipeline highlights include XmAb819 45.5% confirmed ORR at 400 mcg/kg in ccRCC and plans to initiate a Phase 3 study by end of 2027.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $116.5M vs $21.0M YoY, primarily from royalties and milestones
- GAAP diluted EPS $0.50 vs net loss of $(0.08) in Q3 2025
- Consensus was EPS $-0.34 and revenue $63.0M; EPS beat by $0.84, revenue beat by $53.5M
- R&D expenses $84.3M, up from $54.4M YoY, driven by higher program costs
- Cash and marketable securities $555.7M at Sep 30, 2026; guidance for $480M-$500M year-end 2026
- XmAb819 400 mcg/kg IV dose showed 45.5% confirmed ORR in ccRCC; Phase 3 planned by end 2027
- Astellas milestone of $25.0M triggered by ASP2138 Phase 3 first patient dosed
- Zenas BLA for obexelimab accepted by FDA; $2.5M milestone from Japan MAA submission
Financial Impact
Revenue $116.5M vs consensus $63.0M; GAAP EPS $0.50 vs consensus $-0.34; cash burn from operations with $555.7M cash position
Risk Factors
- Revenue beat driven by one-time milestones and settlement payments, not sustainable
- R&D spending increased 55% YoY to $84.3M, pressuring operating cash flow
- Cash burn from operations: cash declined from $610.8M (Dec 2025) to $555.7M (Sep 2026)
- XmAb819 Phase 3 study not yet initiated; regulatory feedback on accelerated pathway pending
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326732-26-000062 |
| Document: xncr-20261104.htm | 0001326732-26-000062 |
| Document: 0001326732-26-000062-index-headers.html | 0001326732-26-000062 |
| Document: 0001326732-26-000062-index.html | 0001326732-26-000062 |
| Document: 0001326732-26-000062.txt | 0001326732-26-000062 |
| 8-K Data (Synthetic) | 0001326732-26-000062 |
Track record
20 reports on XNCR
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +67.24% at T+60 after the May 5, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
- Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers